Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound. The new lawsuits name Thrive Health and Wellness LLC and Valhalla Vitality LLC.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Copycat weight-loss drugs: Eli Lilly sues two medical spas
Two medical spas have been sued by Eli Lilly for selling unapproved products that claim to contain tirzepatide. Tirzepatide is the main ingredient in Zepbound, Lilly's famous
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
What's in the 'Natural Mounjaro' Drink — and Should You Try It?
People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...
Medicine Buffalo2d
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Healthline5d
Mounjaro Diet: What to Eat While on Mounjaro
Weight loss varies by individual, but drug study results can give us a general idea. For example, a 2022 study of tirzepatide (the active ingredient in Mounjaro) prescribed for obesity ...
USA Today26d
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...
Ask a Health Professional: How do semaglutide and tirzepatide support wellness goals?
Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro
When Henry Conway hit his forties his BMI became dangerously high. After a lover said ‘I love your little dad bod’, he knew ...
Gemma Collins reveals she’s dropped two dress sizes after using fat loss injections to lose weight
GEMMA Collins has revealed that she’s dropped two dress sizes after turning to fat loss injections. The TV favourite, 43, who ...